智通财经APP讯，药明康德(02359)发布公告，于2025年10月10日，根据5亿美元于2025年到期的零息有 担保可转换债券而转换及发行1806.46万股H股。 ...

格隆汇10月10日丨药明康德(02359.HK)宣布，董事会将于2025年10月24日（星期五）召开董事会会议， 以考虑及批准（其中包括）集团截至2025年9月30日止九个月的第三季业绩及其发布。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 呈交日期： 2025年10月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | A. 已發行股份或庫存股份變 ...

無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2025年10月24日（星期五）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年9月30日止九個月之第三季業績及其發佈。 香港交易及結算所有限公司及香港聯合交易所有限公司對本 公告 的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本 公告 全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年10月10日 截至本公告日期，董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生；非 執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 ...

Market Overview - The A-share market experienced a day of volatility and adjustment, with all three major indices closing down: Shanghai Composite Index fell by 0.94%, Shenzhen Component Index dropped by 2.70%, and ChiNext Index decreased by 4.55% [1][2] - The total market turnover was 2.53 trillion yuan, a decrease of 137.7 billion yuan compared to the previous day [2] Sector Performance - Gas and coal sectors showed gains, while semiconductor, battery, and precious metals sectors faced significant declines, with semiconductor funds seeing an outflow exceeding 20 billion yuan [2][3] - Notable individual stock movements included CATL and Sanhua Intelligent Control, both experiencing fund outflows over 2 billion yuan, while ZTE Corporation saw a rise of over 4% [4] Precious Metals - The price of spot gold fell below the 4000 USD mark, closing at 3965 USD per ounce, leading to a decline in A-share precious metal stocks, with several stocks like Western Gold and Chifeng Jilong Gold dropping over 5% [8][10] - Analysts suggest that persistent inflation data in the U.S. could lead to a stronger dollar and higher real interest rates, reducing gold's attractiveness [11] Investment Sentiment - The first three quarters of the year saw significant gains in major indices: Shanghai Composite Index up 15.84%, Shenzhen Component Index up 29.88%, and ChiNext Index and Sci-Tech 50 Index both up 51.20% [14] - The best-performing sectors included non-ferrous metals, hardware equipment, and semiconductors, with emerging concepts like AI and controlled nuclear fusion gaining traction [14] - Market sentiment indicates a cautious outlook for the fourth quarter, with a potential shift in investment focus from technology to traditional sectors like real estate and machinery [15]

本次减持对药明康德的财报将产生立竿见影的效果。公司称，出售的药明合联股票在账面上列为"长期 股权投资"。经公司财务部门初步测算，本次出售药明合联的投资净收益对公司2025年度税后净利润的 影响约为16.79亿元，占公司2024年归属净利润的比例超过10%。 药明康德还表示，截至此次出售，2025年累计出售药明合联股票的投资净收益对公司2025年税后净利润 的影响约为43.51亿元。 港股药明合联再次遭到股东药明康德（603259）的减持。药明康德10月9日晚称已减持药明合联3030万 股，套现逾23亿港元。截至发稿，药明康德大跌逾7%，药明合联大跌逾6%。 药明康德公告，公司于10月8日通过大宗交易方式，出售了其间接控股子公司所持有的药明合联3030万 股，约占其总股本的2.47%。此次交易成交金额达到约23.46亿港元（不含交易费用）。 记者注意到，最近一年药明康德已多次减持药明合联。2024年11月、2025年1月药明康德分别减持药明 合联3600万股和5000万股，累计成交金额约24.26亿港元；2025年4月，公司继续减持药明合联5080万 股，成交金额约21.78亿港元。如果加上本次减持，最近一年药 ...

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

最后说贵州茅台，业绩"稳"就是最大的亮点。三季度预告里，营收同比增10%-12%，净利润增11%-13%，增速和二季度差不多，但细节里有惊喜——直销渠 道营收增了25%，占比提到38%，比二季度高了2个百分点，这意味着利润率还能往上走，毕竟直销比经销赚得多。机构持仓方面，社保基金和险资基本没 动，持仓比例和二季度持平，北向资金也只是小幅调了1%，这种"大机构稳拿不动"的状态，正好符合咱们把它当"底仓"的需求，不用怕市场震荡出幺蛾 子。 各位朋友，我是帮主郑重，知道大家看金股不光看逻辑，更要"业绩实不实、机构认不认"——这就把中芯国际、药明康德这些核心标的，近期业绩预告和机 构持仓变化扒得明明白白，咱们看长线也能更踏实。 先看中芯国际，业绩预告里藏着"稳信号"。最新三季度预告显示，营收同比增12%-15%，净利润增8%-10%，虽然增速不算特别猛，但关键在"超预期"—— 市场原本预估净利润增速顶多5%，能超预期靠的就是28nm成熟制程产能拉满，这部分业务营收占比已经提到42%，比二季度又高了3个百分点，说明之前说 的"订单排到2026年"不是虚的。再看机构持仓，三季度公募基金增持了1.2亿股，社保基金也加了20 ...

Core Insights - The Chinese sickle cell disease treatment industry is transitioning from symptomatic treatment to curative treatment, driven by breakthroughs in gene editing technology [1][11] - The market size for sickle cell disease treatment in China is projected to reach approximately 4.287 billion yuan in 2024, representing a year-on-year growth of 66.03% [1][11] Industry Overview - Sickle cell disease is an autosomal recessive genetic disorder caused by mutations in the beta-globin gene, leading to abnormal hemoglobin (HbS) that causes red blood cells to deform into a sickle shape, resulting in hemolysis, vascular occlusion, and multi-organ ischemic damage [2][6] - Current treatment methods include medication, blood transfusions, hematopoietic stem cell transplantation, and gene therapy, with the goal of alleviating symptoms, preventing complications, and improving quality of life [4][11] Industry Development History - The early exploration phase from the 1950s to the 1980s focused on symptom management through blood type screening and family history investigations in high-prevalence areas [6][7] - The standard treatment phase from the 1990s to the 2010s saw the introduction of hydroxyurea and regular blood transfusions, although long-term transfusions led to iron overload [7][11] - The breakthrough phase from the 2010s to present has seen advancements in gene therapy, with significant clinical trials and the approval of therapies like CASGEVY by the FDA [7][11] Industry Value Chain - The upstream of the sickle cell disease treatment industry includes raw materials such as cells, growth factors, and gene editing tools like CRISPR-Cas9 [9][10] - The midstream focuses on research and production of sickle cell disease treatments, while the downstream primarily serves patients suffering from the disease [9][10] Market Size - The sickle cell disease treatment market in China is experiencing significant growth, with a projected market size of approximately 4.287 billion yuan in 2024, reflecting a 66.03% increase from the previous year [1][11] Key Companies' Performance - The industry is characterized by a "technology-driven" competitive landscape, with companies like Zhengxu Bio leading in gene therapy innovations [12][13] - Traditional pharmaceutical companies such as Heng Rui Medicine and Shijiazhuang Pharmaceutical Group leverage their production capabilities and insurance coverage to maintain a strong presence in the basic treatment market [12][13] Industry Development Trends 1. Continuous technological innovation is driving a paradigm shift in treatment approaches, with gene editing tools enabling targeted repair of the beta-globin gene [14] 2. Policy and market developments are fostering industry expansion, with the government prioritizing gene editing in its biopharmaceutical strategy [15] 3. Deepening global collaborations are enhancing the industry ecosystem, with partnerships between multinational and local companies accelerating the localization of gene therapies [16][17]

Core Viewpoint - Multiple companies have announced significant collaborations, sales, and financial forecasts, indicating a dynamic market environment with potential investment opportunities and risks. Group 1: Collaborations and Agreements - Sairus's subsidiary signed a framework agreement with Volcano Engine to collaborate on intelligent robotics technology, focusing on the automotive industry's digital transformation [4] - Lichong Group entered a strategic cooperation agreement with Weijing Intelligent Technology to extend its business into humanoid robotics, enhancing the application of aluminum alloy materials in emerging industries [5][6] Group 2: Stock Transactions and Financial Impact - WuXi AppTec sold 30.3 million shares of WuXi AppTec, amounting to approximately HKD 2.346 billion, impacting its net profit by about RMB 4.351 billion for the fiscal year 2025 [7] - Zhonghuan Environmental Protection announced a change in its controlling shareholder, with a transfer price of RMB 598 million, leading to a resumption of stock trading [8] Group 3: Market Performance and Production Data - Wens Foodstuff reported sales of 3.3253 million pigs in September, generating revenue of RMB 4.975 billion, with a year-on-year price change of -15.16% for live pigs [16] - Muyuan Foods experienced a 22.46% decline in revenue from pig sales, totaling RMB 9.066 billion, with a significant drop in average sales price [17] - Qianli Technology reported a 976% increase in September's production of new energy vehicles, with total vehicle production rising by over 400% [18] Group 4: Profit Forecasts - Guangdong Mingzhu expects a net profit increase of 858.45% to 1071.44% for the first three quarters of 2025, with projected profits between RMB 215.18 million and RMB 262.99 million [19] - Great Material anticipates a net profit increase of approximately 213.92% for the same period, with revenues expected to reach around RMB 3.7 billion [20] - Kinglong Permanent Magnet forecasts a net profit growth of 157% to 179% for the first three quarters of 2025, with profits estimated between RMB 505 million and RMB 550 million [21] Group 5: Shareholding Changes - Huamao Logistics's controlling shareholder plans to increase its stake by RMB 64.5 million to RMB 129 million [24] - Weili announced that some directors and senior management intend to increase their holdings by RMB 6.5 million to RMB 13 million [25] - Qiaoyin Co. plans to reduce its shareholding by up to 6% [26] Group 6: Major Contracts and Bids - *ST Songfa's subsidiary signed contracts for six ultra-large crude oil tankers, with a total value of approximately USD 600 million to USD 900 million [33][34] - Shuangliang Energy won a bid for a project worth RMB 419 million, representing 3.21% of its audited revenue for 2024 [35] - Ningbo Construction's subsidiary won a bid for a construction project valued at RMB 1.41 billion [36]